回复:迷迷糊糊的疱疹系列研究----先从感叹开始
The Phase 1 trial completed with HerpV was a randomized, blinded study designed to determine vaccine safety and immunogenicity with particular focus on induction of cellular immune response.
The results of the study show that HerpV administered with QS21 adjuvant was associated with a significant induction of both CD4+ in 7/7 subjects (100%) and CD8+ in 5/8 subjects (63%) cellular immune response.
This is the first instance of a polyvalent herpes vaccine eliciting both CD4 and CD8 cellular immunity in human subjects. This finding is consistent with the known mechanism of action of HerpV. In addition, HerpV administration (with and without QS-21) was feasible and well tolerated.